Lundbeck to launch key product in Ukraine in 2023
Despite the ongoing Russian invasion of Ukraine, Danish pharmaceutical firm Lundbeck will continue its activities in the war-torn country, where it is planning to launch schizophrenia drug and antidepressant Rexulti/Rxulti in 2023.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Nordea cuts Lundbeck share target week before annual report
For subscribers
Alzheimer's drug wins priority review in Japan
For subscribers